Synopsis: The Hyderabad-based pharma giant has given the green light to repurchase shares at ₹1,475 each, a 10% premium over the current market price. A major Indian pharma giant board approved a ₹800 crore share buyback on April 6, offering shareholders ₹1,475...
SYNOPSIS: Aurobindo Pharma is expected to deliver strong FY26–28 growth, driven by US and EU momentum, biosimilars, Pen-G scale-up, and margin expansion, prompting Motilal Oswal to reaffirm its buy rating with upside potential. Shares of an integrated global...
Fundamental Analysis Of Aurobindo Pharma: Since the outbreak of the pandemic, there has been a greater emphasis on pharmaceutical companies due to the increased attention on global health concerns. One such company in this sector is Aurobindo Pharma. The company’s...
